



PTO/SB/08A/B (09-08)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	08/444,790-Conf. #5612
Filing Date	May 19, 1995
First Named Inventor	Manfred Brockhaus
Art Unit	1646
Examiner Name	Z. Howard
Attorney Docket Number	01017/40451B

Change(s)
to document
/A.E.M/
10/10/2011

U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	A64	5,428,130	06-27-1995	Capon et al.
	A65	5,049,791		
	A66	5,224,887		

Patent documents A65 and A66
Withdrawn by USPTO

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code*-Number*Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	B42	EP-0 394 827	10-31-1990	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		
	C157	FOLKS et al., Tumor necrosis factor α induces expression of human immunodeficiency virus in a chronically infected T-cell clone, PNAS, 86:2365-8 (1989).		
	C158	LEE, Generation of cDNA probes directed by amino acid sequence: cloning of urate oxidase, Science, 239:1288-1291 (1988).		
	C159	MORELAND et al., Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein, New England Journal of Medicine, 337:141-147 (1997).		
	C160	SANDBORN et al., Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial, Gastroenterol., 121:1088-94 (2001).		
	C161	WOZNEY, Using purified protein to clone its genes, Methods in Enzymology, 182:738-751 (1990).		
	C162	Inflammation & Infection: Rheumatoid Arthritis, Drug & Market Development, 67-70 (2003).		
	C163	Letter to the EPO with new Auxiliary request 3 in appeal proc. against EP 0 471 701. 12/31/01		
	C164	Notification of the Examiner during the prosecution of EP 99100703.0. 10/24/00		
	C165	Zavoico, Drug & Market Development, 10(7):235-243 (1999).		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Zachary Howard/	Date Considered	08/02/2011
--------------------	------------------	-----------------	------------

957/529

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.H./